Bihormonal artificial pancreas system improves time in range
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Adults with type 1 diabetes using a fully closed-loop, bihormonal artificial pancreas experienced improved glucose response compared with insulin pump therapy without the need to provide meal or exercise announcements, outpatient data show.

This study aimed to demonstrate the performance and safety of a bihormonal (insulin and glucagon) artificial pancreas (AP) in adults with type 1 diabetes.

In this outpatient, randomized, crossover trial, 2-week fully closed loop glucose control (AP therapy) was compared with 2-week open loop control (patient’s normal insulin pump therapy with a glucose sensor if they had one).

A total of 23 patients were included in the analysis. Time in range (70–180 mg/dL [3.9–10 mmol/L]) was significantly higher during closed loop (median 86.6% of time [interquartile range 84.9–88.5]) compared with open loop.

Conclusively, compared with insulin pump therapy, the bihormonal AP provided superior glucose control, without meal or exercise announcements, and was safe in adults with type 1 diabetes.

Source: https://care.diabetesjournals.org/content/early/2021/01/01/dc20-2106
Like
Comment
Share